Myocardial Fibrosis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Myocardial Fibrosis - Pipeline Review, H1 2016

Myocardial Fibrosis - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Myocardial Fibrosis - Pipeline Review, H1 2016
Published Jun 08, 2016
82 pages — Published Jun 08, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Myocardial Fibrosis - Pipeline Review, H1 2016, provides an overview of the Myocardial Fibrosis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Myocardial Fibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis
- The report reviews pipeline therapeutics for Myocardial Fibrosis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Myocardial Fibrosis therapeutics and enlists all their major and minor projects
- The report assesses Myocardial Fibrosis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Myocardial Fibrosis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Myocardial Fibrosis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Myocardial Fibrosis pipeline depth and

  
Source:
Document ID
GMDHC8186IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables51
  List of Figures51
Introduction61
  Global Markets Direct Report Coverage61
Myocardial Fibrosis Overview71
Therapeutics Development82
  Pipeline Products for Myocardial Fibrosis Overview81
  Pipeline Products for Myocardial Fibrosis Comparative Analysis91
Myocardial Fibrosis Therapeutics under Development by Companies101
Myocardial Fibrosis Therapeutics under Investigation by Universities/Institutes111
Myocardial Fibrosis Pipeline Products Glance122
  Clinical Stage Products121
  Early Stage Products131
Myocardial Fibrosis Products under Development by Companies141
Myocardial Fibrosis Products under Investigation by Universities/Institutes151
Myocardial Fibrosis Companies Involved in Therapeutics Development1610
  AstraZeneca Plc161
  Evotec AG171
  Galectin Therapeutics, Inc.181
  GTx, Inc.191
  Invivosciences, Inc.201
  MandalMed, Inc.211
  miRagen Therapeutics, Inc.221
  Regulus Therapeutics Inc.231
  Shire Plc241
  TRACON Pharmaceuticals, Inc.251
Myocardial Fibrosis Therapeutics Assessment269
  Assessment by Monotherapy Products261
  Assessment by Target272
  Assessment by Mechanism of Action292
  Assessment by Route of Administration312
  Assessment by Molecule Type332
Drug Profiles3526
  AZ-876 - Drug Profile351
    Product Description351
    Mechanism of Action351
    R&D Progress351
  Drugs for Tissue Fibrosis - Drug Profile361
    Product Description361
    Mechanism of Action361
    R&D Progress361
  GM-CT-01 - Drug Profile371
    Product Description371
    Mechanism of Action371
    R&D Progress373
  GRMD-02 - Drug Profile401
    Product Description401
    Mechanism of Action401
    R&D Progress403
  GTx-878 - Drug Profile431
    Product Description431
    Mechanism of Action431
    R&D Progress431
  MGN-4220 - Drug Profile441
    Product Description441
    Mechanism of Action441
    R&D Progress441
  Monoclonal Antibodies for Cardiovascular Diseases - Drug Profile451
    Product Description451
    Mechanism of Action451
    R&D Progress451
  NM-922 - Drug Profile461
    Product Description461
    Mechanism of Action461
    R&D Progress461
  Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile471
    Product Description471
    Mechanism of Action471
    R&D Progress472
  RG-012 - Drug Profile491
    Product Description491
    Mechanism of Action491
    R&D Progress493
  SHP-627 - Drug Profile521
    Product Description521
    Mechanism of Action521
    R&D Progress521
  Small Molecules to Inhibit Soluble Epoxide Hydrolase for Myocardial Fibrosis - Drug Profile531
    Product Description531
    Mechanism of Action531
    R&D Progress531
  SP-20102 - Drug Profile541
    Product Description541
    Mechanism of Action541
    R&D Progress541
  TPI-2049 - Drug Profile551
    Product Description551
    Mechanism of Action551
    R&D Progress551
  TRC-105 - Drug Profile561
    Product Description561
    Mechanism of Action561
    R&D Progress564
  TRC-205 - Drug Profile601
    Product Description601
    Mechanism of Action601
    R&D Progress601
Myocardial Fibrosis Recent Pipeline Updates6118
Myocardial Fibrosis - Dormant Projects791
Myocardial Fibrosis Product Development Milestones801
  Featured News &Press Releases801
    Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter801
Appendix812
  Methodology811
  Coverage811
  Secondary Research811
  Primary Research811
  Expert Panel Validation811
  Contact Us811
  Disclaimer821

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Myocardial Fibrosis - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Myocardial-Fibrosis-Pipeline-Review-H1-2016-2088-15918>
  
APA:
Global Markets Direct - Market Research. (2016). Myocardial Fibrosis - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Myocardial-Fibrosis-Pipeline-Review-H1-2016-2088-15918>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.